Xinxin Si, Yaling Wang, Nianzhuang Qiu, Chenliang Qian, Bochao Yang, Hongwei Jin, Hao Wang, Xuehui Zhang and Jie Xia
RSC Med. Chem., 2025,16, 4731-4741
Abstract
We have discovered a potent DYRK1A inhibitor Y16-5 by virtual screening and in vitro biological evaluation. This compound showed strong in vitro neuroprotective activity and favorable druglikeness.
Mihaela-Liliana Ţînţaş, Ludovic Peauger, Anaïs Barré, Cyril Papamicaël, Thierry Besson, Jana Sopkovà-de Oliveira Santos, Vincent Gembus and Vincent Levacher
RSC Med. Chem., 2024,15, 963-980
Abstract
Promising multitargets ligands in Alzheimer's disease: sequential BuChE and DYRK1A/CLK1 kinases inhibition.
Fengqiu Ma, Yan Ma, Keke Liu, Junying Gao, Shasha Li, Xiaowen Sun and Guorong Li
Food Funct., 2023,14, 1484-1497
Abstract
Schematic representation of resveratrol inducing DNA damage-mediated cancer cell senescence through the DLC1–DYRK1A–EGFR axis.
G. Rajamani, Saba Naqvi and Abha Sharma
RSC Med. Chem., 2026,17, 15-51
Abstract
Structure–activity relationships of GSK-3β inhibitors for Alzheimer's disease.
Mallu Chenna Reddy, Ashutosh Dey, Masilamani Jeganmohan and Kishor Padala
New J. Chem., 2023,47, 16266-16307
From themed collection:
2023 Focus and Perspective articles
Abstract
Aristolactams are a small group of aporphinoid alkaloids containing a phenanthrene chromophore that were first isolated from Aristolochia argentina (Aristolochiaceae), which is the richest source of this family of alkaloids.